Brief: Arcutis Biotherapeutics Q3 basic EPS USD -0.73
03/11/2023 11:36
Nov 3 (Reuters) - Arcutis Biotherapeutics Q3 product revenue USD 8.109 million. * Q3 basic EPS USD -0.73 * Q3 net income USD -44.765 million * Q3 operating expenses USD 75.013 million * Q3 operating income USD -36.904 million
Recent news on Arcutis Biotherapeutics
See all newsBrief: Arcutis Canada Przoryve Cream 0.05% Receives Health Canada Approval For Atopic Dermatitis
Arcutis Biotherapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Arcutis Q2 revenue rises on demand for ZORYVE, lifts 2026 sales outlook
Arcutis Biotherapeutics Inc expected to post earnings of 4 cents a share - Earnings Preview
Brief: Arcutis Biotherapeutics reports inducement grants under Nasdaq listing rule 5635(C)(4